Hikma Pharmaceuticals plc

Hikma is getting ready to make its first launch into the US biosimilars market after receiving US Food and Drug Administration approval for its Starjemza (ustekinumab-hmny) rival to Stelara. Licensed

Hikma has set out ambitious plans to increase its turnover and profit over the next three years, while also setting a longer-term target of achieving group sales of $5bn by 2030. The fresh objectives

With a jury trial previously set to begin later this month, Hikma has reached a preliminary agreement under which it would pay $50m to resolve certain class action antitrust lawsuits brought against t

Viatris has agreed to pay up to $335m as part of a nationwide settlement resolving opioid-related claims by US state and local governments, but admitted no wrongdoing. Under the recently announced fra